Marisa Wexler, MS, senior science writer —

About 2% of people with scleroderma are positive for more than one disease-associated antibody that targets tissues, causing damaging inflammation, according to a new study. Results suggest that certain antibody combinations may be associated with distinct clinical features. The study, “Combinations of scleroderma hallmark autoantibodies associate…

Blocking the activity of calpain proteins reduced scarring in the skin and inflammation in the lungs in a mouse model of scleroderma, a new study shows, suggesting these proteins may be therapeutic targets for this disease. The study, “Myeloid cell-specific deletion of Capns1 prevents macrophage polarization…

June is Scleroderma Awareness Month, and the scleroderma community is working to increase awareness of this rare disease with several campaigns. In a video released at the start of the month, the National Scleroderma Foundation is asking everyone to “know scleroderma.” “To know scleroderma is to understand…

Therapeutic plasma exchange may help ease digestive issues in people with limited systemic scleroderma (lcSSc), new research indicates. Edward Harris of the Scleroderma Education Project presented the findings at the American Society for Apheresis (ASFA) annual meeting in Philadelphia earlier this month, in a poster titled, “The Effects…

Among people with systemic scleroderma (SSc), those who have digital ulcers (DUs) — sores on their fingers or toes — tend to use more healthcare resources, a new study suggests. “Our study demonstrates increased health resource utilization by SSc patients with DUs compared to those without DUs in a…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Treatment with stem cells grown into a skin-like structure called an organoid reduced inflammation and fibrosis (scarring) in a mouse model of localized scleroderma, a new study found. The study, “Application of an iPSC-Derived Organoid Model for Localized Scleroderma Therapy,” was published in Advanced Science.

Two medications — one for arthritis and the other for diabetes — were able to lessen scarring and inflammation in a mouse model of systemic scleroderma (SSc), according to a new study. These results support further research into the medications, tofacitinib and metformin, and others that target the JAK/STAT…

Levels of signaling molecules called cytokines can be used to identify people with systemic scleroderma (SSc) who are at highest risk of developing abnormally high blood pressure in their lungs, a new study reports. The study, “Cytokine signatures differentiate systemic sclerosis patients at high versus low…

Acazicolcept (ALPN-101), an experimental therapy that blocks T-cell activation and is being developed by Alpine Immune Sciences, was found effective at decreasing scarring in mouse models of systemic sclerosis (SSc). A team of scientists at Alpine and other institutions published their findings in a study, “…